PMID- 38371390
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240220
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 17
DP  - 2024
TI  - The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in 
      Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and 
      Meta-Analysis.
PG  - 701-714
LID - 10.2147/DMSO.S443396 [doi]
AB  - AIM: To explore the effects of Tirzepatide (TZP), a new hypoglycemic drug, on 
      weight, blood lipids and blood pressure in overweight/obese patients with type 2 
      diabetes mellitus (T2DM). METHODS: Relevant studies investigating the influence 
      of TZP therapy on weight, lipid profiles and blood pressure in overweight/obese 
      T2DM patients were selected from the PubMed, Embase, Web of Science and Cochrane 
      databases from establishment until November 2022. A systematic review and 
      meta-analysis were conducted to evaluate the effect of TZP on weight, blood 
      lipids and blood pressure in overweight/obese patients with T2DM. RESULTS: Eight 
      randomized controlled trials (RCTs), comprising 7491 patients with T2DM, were 
      included in the meta-analysis. Results showed that compared with the 
      glucagon-like peptide-1 receptor agonist (GLP-1RA), insulin, and placebo groups, 
      body weight, triglycerides (TG), very low-density lipoprotein cholesterol 
      (VLDL-C), total cholesterol (TC), systolic blood pressure (SBP), diastolic blood 
      pressure (DBP), fasting blood glucose (FBG), and glycosylated hemoglobin (HbA1c) 
      levels were significantly decreased in the TZP-treated groups, while high-density 
      lipoprotein cholesterol (HDL-C) levels increased. With the gradual increase of 
      TZP doses, the proportions of T2DM patients with weight loss >5% gradually 
      increased. The 10 mg and 15 mg TZP doses had a stronger effect on the levels of 
      TG, VLDL-C, and HDL-C. Moreover, the reduction in SBP levels in the 15 mg 
      TZP-treated group was more pronounced than those in the 10 mg and 5 mg 
      TZP-treated groups [MD=-2.07, 95% CI (-2.52, -1.63) and MD=-3.14, 95% CI (-4.42, 
      -1.87)]. Compared with GLP-1RA, insulin, and placebo groups, the proportions of 
      patients with HbA1c<7% in 10mg and 15mg TZP-treated groups were significantly 
      higher than in the 5mg TZP-treated group [OR=1.53, 95% CI (1.25, 1.8)], OR=1.7, 
      95% CI (1.15, 2.50)].There was no significant difference regarding the risk of 
      adverse reactions.
CI  - (c) 2024 Lv et al.
FAU - Lv, Xiaoyu
AU  - Lv X
AUID- ORCID: 0000-0003-1491-6506
AD  - The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's 
      Republic of China.
FAU - Wang, Hui
AU  - Wang H
AUID- ORCID: 0009-0007-1135-5068
AD  - The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's 
      Republic of China.
FAU - Chen, Chongyang
AU  - Chen C
AD  - The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's 
      Republic of China.
FAU - Zhao, Yangting
AU  - Zhao Y
AD  - The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's 
      Republic of China.
FAU - Li, Kai
AU  - Li K
AD  - The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's 
      Republic of China.
FAU - Wang, Yawen
AU  - Wang Y
AD  - The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's 
      Republic of China.
FAU - Wang, Liting
AU  - Wang L
AD  - The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's 
      Republic of China.
AD  - Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, 
      Gansu, People's Republic of China.
FAU - Fu, Songbo
AU  - Fu S
AD  - The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's 
      Republic of China.
AD  - Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, 
      Gansu, People's Republic of China.
FAU - Liu, Jingfang
AU  - Liu J
AUID- ORCID: 0000-0003-1908-4454
AD  - The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, People's 
      Republic of China.
AD  - Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, 
      Gansu, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240212
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC10873148
OTO - NOTNLM
OT  - T2DM
OT  - lipid metabolism
OT  - meta-analysis
OT  - tirzepatide
OT  - weight
COIS- The manuscript has no financial relationship with any institution and all authors 
      claim no conflict of interest.
EDAT- 2024/02/19 06:43
MHDA- 2024/02/19 06:44
PMCR- 2024/02/12
CRDT- 2024/02/19 04:25
PHST- 2023/11/02 00:00 [received]
PHST- 2024/01/11 00:00 [accepted]
PHST- 2024/02/19 06:44 [medline]
PHST- 2024/02/19 06:43 [pubmed]
PHST- 2024/02/19 04:25 [entrez]
PHST- 2024/02/12 00:00 [pmc-release]
AID - 443396 [pii]
AID - 10.2147/DMSO.S443396 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2024 Feb 12;17:701-714. doi: 10.2147/DMSO.S443396. 
      eCollection 2024.